NanoViricides Signs Agreement for Ocular Testing of Its Drug Candidates

NanoViricides, Inc. (NYSEMKT:NNVC) announced has entered into an agreement with Baylor College of Medicine (Baylor) for the testing of its nanoviricides® drug candidates in a small animal model of ocular virus infections.
According to the news:

These animal studies will evaluate the efficacy and potency of the Company’s nanoviricides anti-viral agents in certain ocular viral infections. The goal of these studies is to help select clinical drug development candidates for treatment of certain ocular viral diseases including herpes keratitis in humans.

Eugene Seymour, MD, MPH, CEO commented:

We are very pleased to have the Baylor College of Medicine Department of Ophthalmology join our efforts in developing a drug against ocular viral infections including Herpes Keratitis. We believe Dr. Pflugfelder and his lab will be able to guide us in the IND-enabling development of our drug candidates.

Click here to view the full press release.